PreveCeutical Medical Inc. logo

PreveCeutical Medical Inc. (PRVCF)

Market Closed
7 Aug, 20:00
OTCQB OTCQB
$
0. 01
-0
-4.6903%
$
8.63M Market Cap
- P/E Ratio
- Div Yield
41,300 Volume
- Eps
$ 0.01
Previous Close
Add Transaction
Day Range
0.01 0.01
Year Range
0 0.04
Want to track PRVCF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

PRVCF closed Friday lower at $0.01, a decrease of -4.6903% from Thursday's close, completing a monthly decrease of -18.717% or $0. Over the past 12 months, PRVCF stock lost -39.1525%.
PRVCF is not paying dividends to its shareholders.
The last earnings report, released on Dec 31, 2016, missed the consensus estimates by -0.0064%. On average, the company has fell short of earnings expectations by -0.0035%, based on the last three reports.
PreveCeutical Medical Inc. has completed 1 stock splits, with the recent split occurring on May 23, 2018.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NEO-L (CAD).

PRVCF Chart

People also search for

Security Devices International, Inc.
$ 1.02
-0.9709%
Vivos Inc.
$ 0.05
-2.7079%
Telescope Innovations Corp.
$ 0.31
+2.0388%
Inhibitor Therapeutics Inc.
$ 0.06
-27.1605%
Pacific Health Care Organization Inc.
$ 1
0%

PreveCeutical Medical Inc. (PRVCF) FAQ

What is the stock price today?

The current price is $0.01.

On which exchange is it traded?

PreveCeutical Medical Inc. is listed on OTCQB.

What is its stock symbol?

The ticker symbol is PRVCF.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 8.63M.

Has PreveCeutical Medical Inc. ever had a stock split?

PreveCeutical Medical Inc. had 1 splits and the recent split was on May 23, 2018.

PreveCeutical Medical Inc. Profile

Biotechnology Industry
Healthcare Sector
Stephen Van Deventer CEO
OTCQB Exchange
CA74143C1068 ISIN
CA Country
7 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

PreveCeutical Medical Inc. is a health sciences enterprise focused on the creation of preventive and curative treatments that incorporate organic and nature identical substances. The company is pioneering in its approach to addressing significant health issues by working on a pipeline of innovative product solutions with applications ranging from pain management to combating severe diseases such as cancer and diabetes. With its headquarters located in Vancouver, Canada, PreveCeutical Medical Inc. is steadfast in its mission to deliver groundbreaking health solutions that can offer relief and improve the quality of life for patients around the globe.

Products and Services

  • Cannabinoid Sol-Gel Delivery System

    This cutting-edge delivery system leverages the therapeutic potentials of cannabinoids by facilitating a direct nose-to-brain transportation method. The solvent gel technology is designed to offer a non-invasive, efficient solution for treating conditions such as pain, inflammation, seizures, and neurological disorders without the side effects commonly associated with conventional drug delivery systems.

  • Non-Addictive Analgesic for Pain Management

    In response to the global opioid crisis, PreveCeutical Medical Inc. is developing a non-addictive analgesic for pain management. This initiative aims to provide patients suffering from chronic and acute pain a safer, effective alternative to opioid medications, thus significantly reducing the risk of addiction and other related complications.

  • BSV Peptide Program

    The BSV Peptide Program targets the biochemical pathways involved in cancer progression, offering a novel approach to cancer therapy. By focusing on specific peptides that can alter the behavior of cancer cells, this program seeks to reduce tumor growth, prevent metastasis, and potentially enhance the effectiveness of existing cancer treatments through synergy.

  • Dual Gene Therapy for Type 2 Diabetes and Obesity

    Addressing two of the most prevalent chronic conditions worldwide, the dual gene therapy program is poised to revolutionize the treatment landscape for type 2 diabetes and obesity. By targeting the genetic underpinnings of these diseases, PreveCeutical aims to deliver a therapeutic solution that not only manages symptoms but also addresses the root causes, offering a path towards lasting health improvements.

  • Medicinal Cannabis-Based Products

    Expanding its portfolio, PreveCeutical Medical Inc. is also venturing into the development of medicinal cannabis-based products. Recognizing the versatile therapeutic potential of cannabis, the company is exploring various formulations and delivery mechanisms to treat a wide array of conditions, emphasizing safety, efficacy, and patient convenience.

Contact Information

Address: 885 Cambie Street
Phone: 604 416 7777